Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bacterial lysate - Lallemand Pharma

Drug Profile

Bacterial lysate - Lallemand Pharma

Alternative Names: Antibacterial vaccine sublingual - Lallemand Pharma; Bactovax; Bromunyl; GSK-3966271A; Immubron; Ismigen; PIR-05; PMBL - Lallemand Pharma; Polyvalent Bacterial Mechanical Lysate - Lallemand Pharma; Provax; Pulmigen; Respibron; Sublingual antibacterial vaccine - Lallemand Pharma

Latest Information Update: 19 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lallemand Pharma
  • Developer GlaxoSmithKline; Lallemand Pharma
  • Class Antibacterials; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease; Respiratory tract infections
  • Phase III Allergic asthma

Most Recent Events

  • 01 Mar 2019 Phase-II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Sublingual) before March 2019 (GlaxoSmithKline pipeline, March 2019)
  • 11 May 2017 Phase-III development for Allergic asthma (In adolescents, In children) is ongoing in Poland (Sublingual) (Lallemand Pharma website, May 2017)
  • 24 Mar 2014 No development reported - Preregistration for Respiratory tract infections in Russia (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top